Q3 net sales of $85.6 million , down 2% year-over-year Q3 GAAP earnings per share of $0.08 ; non-GAAP adjusted EPS up 27% from Q3 fiscal 2016 Q3 operating cash generation of $14.4 million ; free cash flow generation of $14.0 million Revised FY2017 revenue and adjusted EPS guidance; free cash flow

ALBANY, N.Y. , March 27, 2017 (GLOBE NEWSWIRE) -- AngioDynamics  (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, will host an Investor Day on April 6, 2017 in New York City , beginning at

ALBANY, N.Y. , March 20, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2017 third

ALBANY, N.Y. , March 14, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology/surgery, today announced it has received CE Mark certification for the Solero Microwave

ALBANY, N.Y. , March 08, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer, is

Q2 net sales of $89.0 million , down 0.3% year-over-year Q2 GAAP earnings per share of $0.37 ; non-GAAP adjusted EPS up 36% from Q2 Fiscal 2016 Q2 operating cash generation of $14.9 million ; free cash flow generation of $13.6 million Reiterated FY2017 revenue guidance; increased adjusted EPS and

ALBANY, N.Y. , Jan. 03, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer and

ALBANY, N.Y. , Dec. 20, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2017 second

ALBANY, N.Y. , Nov. 28, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer, is

ALBANY, N.Y. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO) (the "Company"), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the pricing of the previously announced

ALBANY, N.Y. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO) (the "Company"), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that certain of its stockholders (the

New Senior Credit Facility Includes a $100 Million TLA and a $150 Million RCF Board of Directors Authorizes Up to $25 Million in Share Repurchases ALBANY, N.Y. , Nov. 09, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for

ALBANY, N.Y. , Nov. 09, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of Eileen Auen and Jan Stern Reed to the

ALBANY, N.Y. , Nov. 07, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer, is

Q1 net sales of $88.1 million , up 5% year-over-year Q1 GAAP earnings per share of $0.04 ; non-GAAP adjusted EPS of $0.17 Q1 operating cash generation of $7.4 million FY2017 guidance remains unchanged ALBANY, N.Y. , Oct. 05, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider

ALBANY, N.Y. , Sept. 21, 2016 (GLOBE NEWSWIRE) -- AngioDynamics  (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2017 first

ALBANY, N.Y. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer, is

ALBANY, N.Y. , Aug. 08, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer, is

ALBANY, N.Y. , Aug. 01, 2016 (GLOBE NEWSWIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that Avista Capital Partners, LP and affiliated investment

AngioDynamics Issues Statement Regarding Stryker recall of Angiographic Catheters   ALBANY, N.Y., July 27, 2016 -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, issued